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Introduction
Our research group has isolated, by a modiﬁ  ed preplate 
technique [1,2], a population of muscle-derived stem 
cells (MDSCs) from murine post-natal skeletal muscle. 
Th  ese MDSCs were shown to have the ability to 
proliferate in vivo for an extended period of time and the 
capacity to self-renew, and to undergo multilineage 
diﬀ   er en tiation  in vitro and in vivo [2]. Current knowledge 
on the utility of MDSCs for enhancing repair in various 
musculoskeletal tissues and injured cardiac muscle and 
the potential for their use in clinical applications is 
reviewed in several publications [3-5]. Our data show 
that these cells display a high transplantation capacity in 
skeletal muscle and exhibit only limited degrees of 
engraft  ment capacity in cardiac, bone, cartilage, and 
nerve tissues in respective animal model injuries. Th  eir 
success in repairing damaged tissues is attributed, at least 
in part, to their resistance to stress and through the 
paracrine eﬀ  ect that they impart on host tissues. Th  ese 
paracrine eﬀ  ects can stimulate the mobilization of host 
progenitor cells, stimulate the production of new blood 
vessels via neoangiogenesis, and possibly modulate the 
host immune response.
Th   e term paracrine mechanism, used herein, refers to 
eﬀ  ects that are not necessarily limited to the injury site 
but occur throughout the organism. In this review, we 
focus on studies involving MDSCs in enhancing repair 
and improving function in injured heart muscle and 
promoting repair of osteochondral defects in articular 
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© 2011 BioMed Central Ltdcartilage (AC), and explore the possibility that the repair 
is induced by host cell recruitment, angiogenic and/or 
anti-inﬂ  ammatory activities, and not necessarily restric-
ted to the diﬀ  erentiation of the implanted cells in host 
tissue.
Stem cell-mediated therapies for cardiac injuries
Cellular cardiomyoplasty (CCM), cell transplantation for 
cardiac repair, is an alternative therapeutic approach for 
the treatment of congestive heart failure [6,7]. Researchers 
have used a wide variety of cell types for CCM, including 
embryonic and neonatal rodent and porcine cardio  myo-
cytes, fetal smooth muscle cells, AT-1 tumor cardio-
myocytes, human adult and fetal cardiomyocytes, autolo-
gous adult atrial cells, and dermal ﬁ  broblasts  [8-19]. 
Researchers have also identiﬁ  ed more suitable donor cells 
for CCM. Th   e most promising cell populations evaluated 
to date include skeletal muscle myoblasts [20-23], murine 
embryonic stem cells [24,25], bone marrow (BM)-derived 
stem cells, mesenchymal stem cells (MSCs) [17,26-28], 
puriﬁ   ed (enriched) hematopoietic stem cells [29-31], 
blood- and BM-derived endothelial progenitor cells [32-
35], and cardiac stem cells [36-40]. To date, donor cell 
populations used in CCM have demonstrated some 
beneﬁ  cial  eﬀ   ects for the heart, but various ethical, 
biological, and technical concerns limit their suitability 
for use in human patients. Segers and Lee [41] and Gersh 
et al. [42] reviewed reports on randomized and controlled 
studies in a large number of patients treated with 
diﬀ  erent cell therapeutic strategies (autologous, natural, 
or bioengineered cell populations) and the modes of cell 
injection, and provided an evaluation of their suitability 
for clinical use. Other reports have summarized ﬁ  ndings 
on CCM in animal models and clinical reports 
[41,43-44].
Promising data have been generated recently when 
skeletal muscle myoblasts were utilized in several CCM 
human trials [45,46]. Th  e cells were transplanted via 
direct intramyocardial injection and intra-arterial injec-
tion [21-23,47-49] and despite the ability of the engrafted 
skeletal myoblasts to adapt to the cardiac micro  environ-
ment and improve cardiac performance in experimental 
animal models of cardiac injury [21,22,46-50], various 
limitations, including poor cell survival - similar to those 
encountered with myoblast transplantation into skeletal 
muscle - have hindered the overall applicability of this 
therapeutic approach [51-53].
Our group has used MDSCs in cardiac transplantation 
experiments, which display an improved transplantation 
capacity when compared with myoblasts. MDSC engraft-
ment was 25-fold higher than myoblasts in diseased 
hearts (with a mean of 53 donor MDSCs versus 2 donor 
myoblasts found within the injected hearts at 12 weeks 
post-injection) [54]. Importantly, they elicited signiﬁ  cant 
improvements in cardiac function by exhibiting superior 
cell survival and improving angiogenesis [54-56], most 
likely due to their secretion of vascular endothelial 
growth factor (VEGF) [57].
Although the exact origin of mouse MDSCs remains to 
be determined, these cells express the endothelial cell 
marker von Willebrand factor and can spontaneously 
participate in blood vessel formation after being injected 
into skeletal and cardiac muscle [58]. Th  eir  participation 
in blood vessel formation appears to be due to their 
expression of VEGF and by the fact that they can also 
diﬀ  erentiate toward an endothelial cell lineage [2,54]. Th  e 
latter results suggest that a relationship exists between 
mouse MDSCs and endothelial cells. Other types of stem 
cells derived from the walls of blood vessels, including 
mesoangioblasts and perivascular cells, appear to share 
similarities with MDSCs, which also supports our 
hypothesis that a relationship exists between MDSCs and 
endothelial cells. We have also isolated several popula-
tions of muscle-derived cells from human skeletal muscle 
by ﬂ   uorescence-activated cell sorting (FACS) that co-
express myogenic (CD56 and Pax7) and endothelial cell 
markers (CD34, von Willebrand factor, ulex, and VE-
cadherin) both in vitro and in vivo [59-61]. We observed 
that certain types of cells that constitute the walls of 
blood vessels in adult human muscle (endothelial cells, 
myo-endothelial cells, and pericytes) appear to be very 
early myogenic progenitor cells that have high myogenic 
potential, and regenerative capacities in both skeletal and 
cardiac muscles [59,61-63], much like that exhibited by 
murine MDSCs [2]. We have recently observed that a 
greater improvement in left ventricular function was 
observed after the intramyocardial injection of myo-
endothelial cells when compared to hearts injected with 
myoblasts [63]. Transplanted myo-endothelial cells gener-
ated relatively good engraftments within the infarcted 
myo  cardium and also stimulated angiogenesis, attenu-
ated scar tissue formation, and supported the prolifera-
tion and survival of endogenous cardiomyocytes more 
eﬀ   ectively than transplanted myoblasts or endothelial 
cells [63]. In a diﬀ  erent set of preliminary studies, we also 
observed that the injured hearts injected with skeletal 
muscle-derived pericytes displayed signiﬁ  cant improve-
ments in cardiac contraction, greater neoangio  genesis, 
and a signiﬁ  cant reduction in scar area formation when 
compared with hearts injected with phosphate-buﬀ  ered 
saline [64].
Th   ese latter ﬁ  ndings suggest that myo-endothelial cells 
and pericytes likely represent the human counterpart to 
murine MDSCs and consequently comprise a potential 
therapeutic cell source that could provide valuable 
beneﬁ  ts for patients suﬀ  ering from myocardial infarction 
[64]. We have observed that after the implantation of 
murine MDSCs and human muscle-derived cells 
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heart repair is mediated mostly by the host cells. Indeed, 
we have observed that only a small fraction of the donor 
cells can actually be found within the regenerated heart 
tissue, indicating that the host cells must be largely 
contributing to the cardiac repair process [54,63]. Th  ese 
results indicate that the injected cells may act as a 
reservoir of secreting molecules that play a role in the 
repair process without actively diﬀ  erentiating toward a 
cardiomyocyte lineage or by fusing with host cardiac 
cells.
Th  e cell-mediated paracrine and bystander eﬀ  ects on 
cardiac repair have also been observed with other stem 
cell types, including BM-derived cell populations [65-69], 
hematopoietic cells [70], adipose-derived stem cells [71], 
endothelial progenitor cells [72], human blood endo  the-
lial cells [73], and kidney-derived MSCs [74]. Th  ese 
reports support the hypothesis that the beneﬁ  cial eﬀ  ect 
seen with MDSCs is likely due to the increased secretion 
of paracrine factors and not primarily due to the 
diﬀ   erentiation capacity of the donor cells toward a 
cardiac phenotype (for reviews refer to [28,75]), espe-
cially since the cardiac diﬀ  erentiation of these stem cells 
after implantation remains extremely low (Table 1).
In support of this paracrine eﬀ   ect hypothesis, we 
previously reported that inhibiting angiogenesis by 
inject  ing genetically manipulated MDSCs that express 
the anti-angiogenic protein sFlt-1 reduces the regenera-
tion capacity of MDSCs in injured heart. Th  e  ﬁ  ndings of 
this study demonstrated that most of the cells contribut-
ing to the repair process were indeed chemo-attracted to 
the injury site by the injected cells [57]. Although the 
paracrine action of the donor stem cells is widely 
accepted, the origin of the host cells that participate in 
the repair process remains largely unknown. Further 
experiments are underway to determine the type of cells 
and their origins. Likely candidates for the host cells 
involved in the repair process include, but are not limited 
to, BM-derived cells, vascular-derived endothelial pro-
geni  tor cells, inﬂ  ammatory cells and resident tissue stem 
cells. Since it is well established that the vascular supply 
plays a major role in cardiac tissue repair, it is logical to 
speculate that blood vessel-derived cells are also involved 
in the repair process after cardiac injury. Indeed, it has 
already been shown [76-78] in other animal injury 
models that tissue repair induces the mobilization and 
incorporation of BM-derived endothelial progenitor cells, 
suggesting that some of the chemo-attracted host cells 
are perhaps deri  ved from endothelial progenitor cells. It 
is important to bear in mind that promoting angiogenesis 
will bring more blood vessel-derived cells to the injury 
area, but also cells derived from the BM and bloodstream; 
therefore, caution needs be taken when reporting these 
research ﬁ  ndings.
Th  ese results with MDSCs and other stem cell types 
(Table 1) strongly support the fact that a stem cell’s 
multipotent capacity - in this case the ability to diﬀ  er-
entiate into a cardiac lineage - is not a pre-requisite for 
the cell’s ability to readily aid in the repair of an injured 
heart. We cannot exclude that a stem cell’s ability to 
readily undergo cardiac diﬀ  erentiation does not provide 
additional beneﬁ  cial eﬀ  ect for cardiac repair; however, 
this still remains to be veriﬁ   ed experimentally. More 
importantly, we have observed that the ability of MDSCs 
to resist environmental stresses, including oxidative and 
inﬂ  ammatory stresses, through the cells’ high antioxidant 
capacity (via glutathione and superoxide dismutase), 
plays a major role in the high regenerative capacity of 
MDSCs in various tissues, including the heart [79,80]. 
Moreover, we have observed that treating MDSCs with 
the reducing agent glutathione signiﬁ  cantly reduced their 
ability to repair the heart, supporting our driving hypo-
thesis that a cell’s ability to survive within the injured 
tissue is more important than its terminal diﬀ  erentiation 
potential [79]. A population of stem cells that could 
survive better in this type of harsh environment could 
enhance the regeneration process, potentially through an 
increase in their paracrine eﬀ  ect (for example, increased 
angiogenesis).
A recent study showed that preconditioning BM-
derived MSCs prior to their transplantation enhanced 
their capacity to repair infarcted myocardium, which was 
attributable to an improvement of donor cell survival and 
an increase in angiogenesis/vascularization and pro-
angiogenic factors [81]. In addition, Pasha et al. [82] 
reported that preconditioning cells with the chemokine 
stromal-derived factor 1 alpha (SDF-1) could signiﬁ  cantly 
enhance BM-derived MSC survival, vascular density, 
engraftment, and myocardial function [82]. MSCs derived 
from adult BM genetically modiﬁ   ed with the anti-
apoptotic gene Bcl-2 enhanced cell survival, engraftment, 
revascularization, and functional improvement in a rat 
left anterior descending ligation model of myocardial 
infarction via an intracardiac injection [83]. Taken 
together, these results suggest that a cell’s ability to 
survive the harsh microenvironment within the injured 
heart represents a major determinant for its regenerative 
capacity. Surviving cells can eventually promote the 
repair process primarily through a paracrine eﬀ  ect that 
involves angiogenesis, especially for cardiac repair 
(Figure 1).
Finally, it is important to state that stem cells with 
cardio  myocyte properties (such as cardiac stem cells, 
embryonic stem cells or genetically engineered cells with 
cardiomyocyte inducers) are perhaps more likely to 
terminally diﬀ  erentiate into cardiomyocytes and partici-
pate in heart repair than stem cells incapable of 
diﬀ  erentiating toward a cardiac lineage. It is possible that 
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Page 4 of 12cardiac diﬀ  erentiation of stem cells prior to their trans-
plantation could improve cardiac function due to their 
ability to integrate more eﬀ   ectively with the host 
myocardium. It will also be important to determine 
whether diﬀ  erentiating the cells toward a cardiac lineage 
prior to their implantation could inﬂ  uence the paracrine 
eﬀ  ect of the stem cells and how this would inﬂ  uence their 
action in the cardiac repair process. Th  us far, however, 
from our observations and reports in the literature 
(Table 1), very few post-natal stem cells have been shown 
to adopt a cardiomyocyte phenotype, yet the vast 
majority of transplanted stem cell types have been shown 
to improve cardiac function.
Stem cell therapy for articular cartilage repair
In this section, we investigate the paracrine eﬀ  ect of stem 
cell therapy in the AC repair process of osteoarthritis 
(OA), where the cells used (MDSCs) have the ability to 
undergo chondrogenic diﬀ  erentiation but the paracrine 
eﬀ  ect of the donor cells on the promotion of angiogenesis 
is not required, but, in fact, needs to be inhibited. 
Th   erefore, it is important to determine, in this situation, 
whether the paracrine eﬀ  ect of the stem cells on the local 
microenvironment also plays a major role in the 
regenerative capacity of the stem cells for AC repair, 
without relying on angiogenic-related cells (blood vessel- 
and circulation-derived stem cells).
OA is a chronic degenerative joint disorder with world-
wide impact that is primarily characterized by AC 
destruction and osteophyte formation. One of the chief 
mediators of OA is inﬂ  ammation and angiogenesis. Yin 
and Paciﬁ   ci [84] demonstrated that VEGF treatment 
during early limb bud development in chick embryos 
causes excess vascularization and consequently reduced 
condensation of the chondrogenic mesenchyme. In the 
growth plate, VEGF has been reported to play an 
essential role in cartilage vascularization and absorption 
of hypertrophic chondrocytes, which together lead to 
endo chondral  ossiﬁ  cation [85-87]. On the other hand, 
when VEGF was blocked with the soluble receptor 
protein (sFlt-1), it led to the expansion of a zone of hyper-
trophic cartilage and the inhibition of cartilage resorption 
[86]. Similar to endochondral ossiﬁ  cation,  osteophyte 
formation during OA development has been reported to 
involve VEGF signaling [88]. For an extensive review on 
the relationship between angiogenesis and OA in humans 
and animal model studies, we refer our readers to the 
review by Ashraf and Walsh [89], who outlined the 
complexity of OA and the interrelationship between 
angio genesis,  inﬂ  ammatory processes, damage, innerva-
tion, and pain perception in the joint.
Recent data reveal that the expression of VEGF and its 
receptors (Flt1 and Flk1) in osteoarthritic cartilage 
reﬂ   ects the ability of VEGF to enhance catabolic 
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Page 5 of 12pathways in chondrocytes by stimulating matrix metallo-
protein  ase activity and reducing tissue inhibitors of 
matrix metalloproteinases (TIMPs) [90-93]. Th  ese data 
suggest that, apart from the eﬀ  ect of VEGF on cartilage 
vascularization and proliferation of cells in the synovial 
membrane, chondrocyte-derived VEGF promotes cata-
bolic pathways in the cartilage itself, thereby leading to a 
progressive breakdown of the AC extracellular matrix.
Since AC is a tissue type that is poorly supplied by 
blood vessels (avascular), nerves, and the lymphatic 
system, it has a very limited capacity for repair after 
injury. Although several therapies have been used to treat 
OA, no widely accepted treatments have been estab-
lished, with the exception of arthroplasty. For this reason, 
tissue engineering techniques aimed at repairing AC have 
been extensively studied and chondrocyte transplantation 
is currently performed in clinics [94-96]. Th  e current 
most eﬀ  ective OA treatment, besides arthroplasty, is the 
use of autologous chondrocyte transplantation. However, 
this treatment has several limitations, including the use 
of neighboring healthy donor cartilage, diﬃ   culty  in 
treating large-scale defects, limited expansion capacity of 
the primary chondrocytes, the need for a periosteal patch 
to maintain engineered cartilage, and the fact that, in 
most cases, only 30 to 40% of the defect regenerates AC, 
with the remaining defect being ﬁ  lled with ﬁ  brocartilage 
[97-99]. In light of these limitations, it is important to 
ﬁ  nd other sources of cells that are abundant and capable 
of chondrogenic diﬀ   erentiation. Stem cells are more 
attrac  tive than primary chondrocytes because of their 
Figure 1. The mechanism(s) of action of implanted stem cells and their regenerative capacity. After implantation in injured tissue, cell 
survival plays a major role in the repair process. The cell’s ability to survive consequently leads to better long-term proliferation, self-renewing ability, 
and multipotent diff  erentiation capacity, but the main eff  ect within the injured tissue appears to be as a reservoir for secreting molecules that can 
induce a variety of paracrine eff  ects, especially chemo-attraction. The paracrine eff  ect may have a major infl  uence on the local microenvironment 
(blocking angiogenesis in articular cartilage) or on the systemic environment that involves the recruitment of host cells from the systemic 
circulation (increasing angiogenesis in the heart). The systemic eff  ect appears to be primarily involved with angiogenesis, which is responsible for 
bringing a multitude of stem cells to the injured tissues.
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Page 6 of 12superior capacity for self-renewal, proliferation, and 
survival follow  ing microenvironmental stress. Recently, 
stem cell-based therapies have been used clinically for 
cartilage repair [100,101]. Several studies have suggested 
that stem cells can undergo chondrogenesis and repair 
AC in experi  mental cartilage injury models 
(osteochondral lesions), including studies using MDSCs 
[102]. We have already reported that bone morphogenetic 
protein (BMP)4-transduced MDSCs improve cartilage 
regenera tion  in  in vitro pellet cultures and in an in vivo 
cartilage defect model (osteochondral defect) [102]. We 
have also shown recently that human muscle-derived 
cells (myo-endothelial cells and pericytes) can undergo 
chondro genic  diﬀ  erentiation in vitro, albeit to a diﬀ  erent 
extent [61,62].
Since the expression of VEGF by chondrocytes in the 
osteoarthritic joint has been related to cartilage destruc-
tion [88,90,91,93,103-105] and the induction of arthritis 
(especially when the dosage reached a certain threshold) 
[106-108], it is likely that blocking VEGF would prove to 
be a beneﬁ   cial means of preventing or delaying the 
progression of OA. Th   is hypothesis was recently 
supported by the fact that treatment with sFlt-1 (a VEGF 
antagonist) decreased the severity of arthritis in a murine 
model [86,109,110] and our recent observation that the 
injection of MDSCs expressing both BMP4 and sFlt-1 
improved AC repair in a more eﬀ  ective manner than 
MDSCs expressing just BMP4 [111,112]. Our results 
suggest that sFlt-1/BMP4-transduced MDSCs, which 
were transplanted intra-capsularly into an OA rat model, 
enhanced AC regeneration via BMP4’s autocrine/
paracrine eﬀ   ects, and contributed to an appropriate 
environment that prevented chondrocyte apoptosis by 
blocking the intrinsic VEGF catabolic pathway and by 
extrinsic VEGF-induced vascular invasion. Treatment of 
MDSCs with sFlt-1 and BMP4 combined is potentially an 
eﬀ  ective therapy for OA repair that may improve the 
quality and persistence of regenerated AC [111]. Since 
the cells were injected into the joint ﬂ  uid, most of the 
injected cells do not primarily contribute to the regenera-
tion of the AC through their diﬀ  erentiation into chondro-
cytes; instead, they chemo-attract host cells to the injury 
site, which are the cells primarily seen in the regenerated 
tissue. We are performing experiments to determine the 
origin of these host cells that participate in the repair 
process by testing the role of inﬂ  ammatory/immune, BM 
and synovial cells. Since we have observed that the 
injection of muscle-derived cells (isolated from rabbit 
skeletal muscle) in the joint ﬂ  uid of rabbits leads to a 
massive attachment of the injected cells in the synovium 
[113], we posit that synovium-derived cells are implicated 
in the repair process.
Although the mechanism behind the beneﬁ  cial eﬀ  ect of 
blocking angiogenesis in AC repair is still not fully 
elucidated, these results highlight the importance of 
controlling the local microenvironment by reducing 
angio genesis.  Th  erefore, the reduction of angiogenesis 
eliminates the mobilization of blood vessel wall- and 
circulation-derived progenitor cells and thus their 
recruitment and diﬀ  erentiation toward a chondrogenic 
lineage, which demonstrates the paracrine eﬀ  ect that the 
implanted stem cells exert on the local microenvironment 
for optimizing the AC repair process (Figure 1).
Recently, Gelse and colleagues [114] reported that 
transplanted rib chondrocyte spheroids could repair a 
cartilage defect in a miniature pig model by producing 
BMP2 and attracting the host’s BM-derived cells. Th  e 
transplanted chondrocyte spheroids provided a stimula-
tory paracrine eﬀ   ect that induced the in-growth and 
chondrogenic ability of the host BM-derived cells. Th  is 
paracrine eﬀ  ect was observed to be far more important 
to the repair process than the direct diﬀ  erentiation of the 
transplanted cells into chondrocytes. Although the 
transplanted cells enhanced the tissue repair process, 
these experiments further validate our hypothesis that 
the AC repair process, even using stem cells other than 
MDSCs, also relies on the paracrine eﬀ  ect that the donor 
cells impart on the host cells.
The microenvironment infl  uences the fate of stem 
cells
BMP4-transduced MDSCs can undergo osteogenesis and 
promote bone repair when injected into a bone defect 
[115-117], which is diﬃ   cult to explain given that similar 
BMP4-transduced cells can promote the repair of AC 
when injected into an osteochondral defect. Th  is 
phenomenon, however, is a good example of how the 
microenvironment inﬂ  uences the regenerative ability of 
the transplanted stem cells. After a bone or AC injury 
occurs, a multitude of signals are released at the site of 
injury. It is likely that the chemotaxis of host cells is 
enhanced by growth factors and cytokines produced by 
the donor cells, which are in turn aﬀ   ected by their 
interaction with the extra  cellular matrix at the injury site. 
Speculatively, stem cells injected into the site could aid 
and enhance the mediation of the repair process; 
however, knowing that the repair process relies primarily 
on host cell participation, it is easier to understand why 
BMP4-expressing MDSCs have a beneﬁ  cial eﬀ  ect on both 
bone and AC repair since the repair process does not rely 
on the terminal diﬀ  er  en  tiation of the donor cells per se. 
Furthermore, Blanke et al. [118] have shown that 
successful repair of cartilagi  nous tissue after 
transplantation of chondrocytes was associated with 
their production of thrombo  spondin-1 and 
chondromodulin-I anti-angiogenic proteins. Th  ey  found 
that tissues resisted ossiﬁ  cation when the chondro  cytes 
produced detectable levels of anti-angiogenic proteins, 
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cells. It is very likely that MDSCs react in a similar 
manner to the local environmental cues and produce 
anti-angiogenic proteins similar to thrombo  spondin-1 
and chondromodulin-I when in a cartilaginous 
microenvironment, a hypothesis that will need to be 
further investigated in future studies.
Another example that demonstrates the inﬂ  uence of 
the microenvironment is the fact that the regenerative 
capacity of stem cells has been shown to be inﬂ  uenced by 
the age of both the host- and the donor-derived stem 
cells [119]. Th   e results showed the rejuvenation of aged 
progenitor cells after their exposure to a young systemic 
environment where a young and aged mouse had their 
circulatory systems linked by heterochronic parabiosis. 
Th  ese ﬁ   ndings highly implied that the proliferative 
property of satellite cells obtained from old mice is 
restored after incubation with the serum from a young 
animal. Th   ese results further support our hypothesis that 
the regenerative process of given stem cells is strongly 
inﬂ  uenced by signals found within the microenvironment.
Furthermore, we have recently observed that the re-
genera  tive capacity of stem cells also appears to be inﬂ  u-
enced by the gender of the donor cells and the host. In 
fact, we reported that female MDSCs are more myogenic 
and can promote muscle regeneration in a more eﬀ  ective 
manner than male MDSCs [120]. On the other hand, 
male MDSCs were shown to be more osteogenic and 
chondrogenic and promoted both bone and AC repair in 
a more eﬀ  ective manner than their female counterparts 
[111,121]. Although the mechanisms behind these gender 
diﬀ  erences are still unclear, we have shown that the host 
microenvironment is also inﬂ  uenced by the gender of the 
animal and plays a role in the eﬃ   ciency of the repair 
process. Indeed, we have reported that bone formation 
mediated by male MDSCs is superior in a male host 
versus that of a female host [121]. Interestingly, female 
MDSCs produce better bone when injected into a male 
host when compared to a female host. Th  ese results 
further support our hypothesis that the microenviron-
ment inﬂ  uences the fate and regenerative potential of the 
injected stem cells.
Conclusion
Although it has been speculated for numerous years that 
the high regenerative potential of stem cells is due to 
their terminal diﬀ  erentiation capacity, current ﬁ  ndings 
appear to indicate that very few donor cells actually 
diﬀ  erentiate and participate in the regeneration of these 
injured tissues; instead, the vast majority of the cells 
reconstituting the regenerated tissues are host-derived. 
Th  ese ﬁ  ndings are further supported by recent results 
showing that when the paracrine signaling of the 
implanted stem cells is interrupted (that is, by blocking 
VEGF and angiogenesis), there is a reduction in the 
regeneration and repair capacity of the injured tissues, as 
is the case for cardiac muscle repair. Although it is still 
unclear which host cells are involved in the repair 
processes after stem cell transplantation, blood vessel 
cells, immune and inﬂ  ammatory cells and resident cells 
at the site of the injury (especially for AC damage), 
appear to play a role in the regeneration/repair process. It 
is quite clear, however, that the terminal diﬀ  erentiation of 
stem cells does not represent a major determinant for the 
success of stem cell therapy; instead, it appears that 
donor cell survival and the cells’ paracrine eﬀ  ect play 
much more critical roles in the success of stem cell 
therapy. Th  is  ﬁ  nding challenges current dogma indicating 
that embryonic stem cells may have an advantage over 
adult-derived stem cells because of their higher level of 
multipotentiality. We therefore put forward the propo-
sition that it is the stem cell’s superior cell survival 
capacity that leads to its increased ability to chemo-
attract host cells through the secretion of certain growth 
factors and chemokines and this is the key important 
feature for successful stem cell therapy, more so than 
stem cells’ terminal diﬀ  erentiation capacity.
Future directions
Th  e paradigm shift in evaluating stem cell engraftment 
based on their terminal diﬀ   erentiation into host cells 
underscores the need to understand the biology of stem 
cells to fully utilize their potential. Furthermore, we are 
increasingly aware that stem cells alone are not suﬃ   cient 
for a long lasting regenerative eﬀ  ect. Th  e ultimate goal 
would thus be the generation of tissues incorporating 
stem cells, scaﬀ  olds and biological materials that permit 
communication with host tissues, allowing optimal 
remodeling and improved functionality. Future regenera-
tive schemes may include cells and a complex milieu of 
factors based on a rigorous understanding of stem cells’ 
paracrine secretions. Computer-aided bioreactors, bio-
printers, artiﬁ  cial or decellularized organs and other bio-
devices could also beneﬁ  t from knowledge of stem cells’ 
paracrine activities.
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